Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• BREAKWATER pivotal data further establish the benefit of BRAFTOVI regimen following FDA full approval and topline results announcement for objective response rate from Cohort 3

  60% confidence

• These results reinforce Pfizer's ability to advance breakthroughs that may redefine clinical practice and change the lives of people with cancer

  60% confidence

• For people living with cancer and their families, every moment matters. We are moving with urgency to drive advances that have the potential to change standards of care – and striving to bring new, innovative options to patients in earlier lines of therapy

  60% confidence

• Data highlights Pfizer's leadership in establishing potential new standards of care across multiple cancer types and its next-generation pipeline of novel targets and combination strategies designed to extend impact into broader patient populations and earlier lines of therapy

  60% confidence

• Seven-year update from CROWN study further supports LORBRENA as a guideline-recommended first-line treatment for anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer

  60% confidence

• The progress is evident in the data presented at ASCO this year, which span the portfolio of established therapies, as well as next-generation, early-stage clinical research from one of the industry's largest oncology R&D programs

  60% confidence

Data points we hold from this source